Literature DB >> 1511461

The augmentation of lymphokine-activated killer activity following pulsing of human peripheral blood mononuclear cells with recombinant human interleukin-2.

C R Carter1, B W Hancock, R C Rees.   

Abstract

The short-term exposure of peripheral blood mononuclear cells (PBMC) to recombinant human interleukin-2 (rhIL-2) at 37 degrees C leads to the generation of lymphokine-activated killer (LAK) activity similar in magnitude to that obtained by the exposure of PBMC to rhIL-2 continuously for 3-5 days. In order to investigate whether the required signal for LAK induction occurred during the short exposure to rhIL-2 or at a later point in the induction phase, PBMC were exposed to rhIL-2 for 1 h at 4 degrees C and then exposed to a low-pH wash to remove bound IL-2 from its receptor. PBMC treated in such a way showed increased LAK activity and proliferation compared to cells exposed to rhIL-2 alone. Expression of the p55 (alpha) subunit of the IL-2 receptor was also increased. In order to cause the augmentation, a lowering of the pH below 4.0 was necessary, and exposure of PBMC to low pH alone (in the absence of rhIL-2) failed to cause activation. Another relevant feature was a transient increase in the expression of the p75 subunit of the IL-2 receptor (beta chain) immediately following the exposure to low pH and the release of interferon gamma, tumour necrosis factor alpha and IL-6; activation was blocked by the inclusion of neutralising antisera raised against rhIL-2 and interferon gamma, thus demonstrating that the endogenous release of these cytokines is important for activation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1511461     DOI: 10.1007/bf01789333

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  35 in total

1.  Interleukin-2 activated human killer lymphocytes: lack of involvement of interferon in the development of IL-2-activated killer lymphocytes.

Authors:  N K Damle; L V Doyle
Journal:  Int J Cancer       Date:  1987-10-15       Impact factor: 7.396

2.  Interleukin-2-induced tumor necrosis factor-alpha (TNF-alpha) gene expression in human alveolar macrophages and blood monocytes.

Authors:  R M Strieter; D G Remick; J P Lynch; R N Spengler; S L Kunkel
Journal:  Am Rev Respir Dis       Date:  1989-02

3.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

4.  Endocytosis and degradation of murine anti-human CD3 monoclonal antibodies by normal and malignant T-lymphocytes.

Authors:  O W Press; J A Hansen; A Farr; P J Martin
Journal:  Cancer Res       Date:  1988-04-15       Impact factor: 12.701

5.  Monoclonal antibody internalization and degradation during modulation of the CD3/T-cell receptor complex.

Authors:  L Schaffar; A Dallanegra; J P Breittmayer; S Carrel; M Fehlmann
Journal:  Cell Immunol       Date:  1988-10-01       Impact factor: 4.868

6.  Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2.

Authors:  J J Mulé; S Shu; S L Schwarz; S A Rosenberg
Journal:  Science       Date:  1984-09-28       Impact factor: 47.728

7.  The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo.

Authors:  J J Mulé; S Shu; S A Rosenberg
Journal:  J Immunol       Date:  1985-07       Impact factor: 5.422

8.  Lymphokine-activated killer cells. Analysis of progenitors and effectors.

Authors:  J R Ortaldo; A Mason; R Overton
Journal:  J Exp Med       Date:  1986-10-01       Impact factor: 14.307

9.  Internalization of interleukin 2 is mediated by the beta chain of the high-affinity interleukin 2 receptor.

Authors:  R J Robb; W C Greene
Journal:  J Exp Med       Date:  1987-04-01       Impact factor: 14.307

10.  Activation of natural killer cells via the p75 interleukin 2 receptor.

Authors:  J H Phillips; T Takeshita; K Sugamura; L L Lanier
Journal:  J Exp Med       Date:  1989-07-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.